GlassScriptPhysician profile
Rhys Ishihara
NPI 1962026385
$12,506.33
in general payments reported to CMS, 2019-2025
19 companies · $6,804 in 2025
The $6,804 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.30 · 2021: $320 · 2022: $226 · 2023: $920 · 2024: $4,221 · 2025: $6,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,135 · Honoraria: $2,100 · Travel and Lodging: $1,872 · Long Term Medical Supply Or Device Loan: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,135.30 |
| Honoraria | $2,100.00 |
| Travel and Lodging | $1,871.92 |
| Long Term Medical Supply Or Device Loan | $838.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,875.14 | 2020-2025 | Unity, Hydrus Microstent, Rocklatan |
| New World Medical,INC. | $2,723.69 | 2024-2025 | Streamline, Ahmed Glaucoma Valve, Clearpath |
| Abbvie INC. | $2,689.60 | 2023-2025 | |
| Sight Sciences, INC. | $1,173.13 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $868.22 | 2023-2025 | Tecnis Simplicity, Catalys System, Veritas Vision System |
| Glaukos Corporation | $534.73 | 2024-2025 | Idosetr, Istent Infinite, Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $378.36 | 2023-2025 | Envista Envy Iol, Stellaris, Ic-8 Apthera Iol |
| Horizon Therapeutics Plc | $249.39 | 2023 | Tepezza, Uplizna |
| Dompe US, INC. | $222.07 | 2021-2024 | Oxervate |
| Sun Pharmaceutical Industries INC. | $150.69 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $121.86 | 2023 | Eylea Hd |
| Tarsus Pharmaceuticals, INC. | $107.19 | 2025 | Xdemvy |
| Allergan, INC. | $99.99 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.90 | 2021 | |
| Genentech USA, INC. | $85.50 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.83 | 2025 | Tepezza |
| Biotissue Holdings INC. | $40.80 | 2024 | |
| Rxsight INC | $21.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhys Ishihara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.